TABLE 5.

Clinical characteristics across ACTN3 and VDR genes polymorphisms.

SNPs	BASDAI			BASFI			BASMI
	Cases n (%)		p-value*	Cases n (%)		p-value*	Cases n (%)		p-value*
	No active disease	Active disease		Low functional repercussion	High functional repercussion		Mild score	Severe score		Controls n (%)
ACTN3 R577X
C/C	6 (28.6)	2 (40.0)		6 (27.3)	2 (50.0)		8 (34.8)	0 (0.0)		6 (25.0)
C/T	12 (57.1)	3 (60.0)	0.700	13 (59.1)	2 (50.0)	0.633	12 (52.2)	3 (100.0)	0.398	12 (50.0)
T/T	3 (14.3)	0 (0.0)		3 (13.6)	0 (0.0)		3 (13.0)	0 (0.0)		6 (25.0)
VDR—FokI
A/A	3 (14.3)	1 (20.0)		3 (13.6)	1 (25.0)		4 (17.4)	0 (0.0)		2 (8.3)
A/G	9 (42.9)	3 (60.0)	0.534	9 (40.9)	3 (75.0)	0.247	9 (39.1)	3 (100.0)	0.188	16 (66.7)
G/G	9 (42.9)	1 (20.0)		10 (45.5	0 (0.0)		10 (43.5)	0 (0.0)		6 (25.0)
VDR—TaqI
A/A	9 (42.9)	2 (40.0)		11 (50.0)	0 (0.0)		10 (43.5)	1 (33.3)		7 (30.4)
A/G	5 (23.8)	2 (40.0)	0.810	5 (22.7)	2 (50.0)	0.323	6 (26.1)	1 (33.3)	0.886	9 (39.1)
G/G	7 (33.3)	1 (20.0)		6 (27.3)	2 (50.0)		7 (30.4)	1 (33.3)		7 (30.4)
VDR—ApaI
C/C	6 (28.6)	1 (25.0)		7 (31.8)	0 (0.0)		6 (26.1)	1 (50.0)		3 (12.5)
C/A	7 (33.3)	2 (50.0)	0.692	8 (36.4)	1 (33.3)	0.415	9 (39.1)	0 (0.0)	0.528	10 (41.7)
A/A	8 (38.1)	1 (25.0)		7 (31.8)	2 (66.7)		8 (34.8)	1 (50.0)		11 (45.8)

*p-value χ²-test; BASDAI < 4, “no active disease”; BASDAI ≥ 4 “active disease”; BASFI < 4 “low functional repercussion”; BASFI ≥ 4 “high functional repercussion,” and BASMI < 3, low reduction, BASMI ≥ 3, high reduction in movement amplitude.